Sindhu Malapati, MD
Hematology & Oncology · Little Rock, ARNPI 1407232184
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $527 of the $827 with a category attached, or 63.7%. 18 manufacturers reported payments, led by AstraZeneca at 24.0% of the total. Reporting peaked in 2019 at $732 and has fallen 92.7% since, to $53 in 2023. That places this record below the midpoint for hematology & oncology clinicians in AR, where the typical reported total is $4,667.
Across 23 payments — averaging $35.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$199
- Bayer$125
- Genentech USA, Inc.$125
- Sanofi-aventis U.S. LLC$76
- Genentech, Inc.$53
- Bristol Myers Squibb$31
- plus $218 from 12 others
Across 5 payments — averaging $2936.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$15K
What the payments were for
- Food & beverage$52764%
- Education$30036%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 3 | $199 |
| Bayer | 1 | $125 |
| Genentech USA, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $76 |
| Genentech, Inc. | 1 | $53 |
| Bristol Myers Squibb | 2 | $31 |
| Amgen | 2 | $29 |
| Incyte Corporation | 2 | $28 |
| Lilly USA, LLC | 1 | $22 |
| Terumo BCT, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Sanofi | 1 | $16 |
| AbbVie | 1 | $16 |
| Array Biopharma Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$827 in reported general payments places this provider in the 25th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 50 | $615,689 |
| IbrancePalbociclib | 33 | $509,524 |
| VerzenioAbemaciclib | 20 | $282,902 |
| EliquisApixaban | 26 | $16,993 |
| Anastrozole | 157 | $2,977 |
| Exemestane | 31 | $2,770 |
| Tamoxifen Citrate | 62 | $2,250 |
| Letrozole | 61 | $977 |
| Gabapentin | 53 | $715 |
| Ondansetron OdtOndansetron | 42 | $578 |
| Prochlorperazine Maleate | 26 | $435 |
| Oxybutynin Chloride | 18 | $340 |
| Potassium Chloride | 18 | $313 |
| Duloxetine Hcl | 12 | $222 |
| Oxycodone Hcl | 13 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $14 | $526,51859 claims |
| Lilly USA, LLCVerzenio | $22 | $282,90220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Little Rock
- Frits van RheeLittle Rock$218K
- Appalanaidu SasapuLittle Rock$63K
- Peter EmanuelLittle Rock$53K
- Brad BaltzLittle Rock$25K
- Carolina SchinkeLittle Rock$23K
- Pooja MotwaniLittle Rock$21K
- Naveen YarlagaddaLittle Rock$18K
- Joseph BeckLittle Rock$16K
- Konstantinos ArnaoutakisLittle Rock$12K
- Abhijit GodboleLittle Rock$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.